| 中文名称 | 英文名称 | CAS号 | 化学式 |
|---|---|---|---|
| GPR109A受体激动剂(MK-0354) | MK-0354 | 851776-28-8 | C7H8N6 |
| GNF179代谢物 | 2-(4-Fluorophenyl)-8,8-dimethyl-5,6,7,8-tetrahydroimidazo[1,2-A]pyrazine | 1310455-86-7 | C14H16FN3 |
| FR180204,一种ATP-竞争性的选择性的ERK抑制剂 | FR180204 | 865362-74-9 | C18H13N7 |
| FR167653硫酸盐 | FR167653 | 158876-66-5 | C24H18FN5O2*H2O4S |
| ERK抑制剂II,阴性对照 | ERK Inhibitor II, Negative Control | 1177970-73-8 | C18H12N6O |
| EBP氯代物杂质 | 5'-Chloro eltrombopag | 376592-56-2 | C25H21ClN4O4 |
| DNA荧光探针前驱体,DNA小沟配体 | 4-(1-methylimidazole-2-carboxamido)-1-methylimidazole-2-carboxylic acid | 464892-44-2 | C10H11N5O3 |
| DNA荧光探针前驱体,DNA小沟配体 | 4-(1-methylpyrrole-2-carboxamido)-1-methylimidazole-2-carboxylic acid | 537049-66-4 | C11H12N4O3 |
| D-甘油-五酸,5-氯-2,3,5-三脱氧-2-(1-甲基乙基)-5-羰基-,g-内酯,(4x)-(9CI) | 3-(o-Chlorobenzyl)-4,5-dimethylthiazolium chloride | 94134-35-7 | C12H13Cl2NS |
| Cav2.2阻滞剂1 | 5-(4-chlorophenyl)-1-(2-methoxyphenyl)-3-(2,2,6,6-tetramethyltetrahydropyran-4-yl)-1H-pyrazole | 1567335-29-8 | C25H29ClN2O2 |
| CP-66713甲磺酸盐 | CP 66713 mesylate | 91896-58-1 | CH4O3S*C15H10ClN5 |
| CP-547632盐酸盐 | 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]-4-isothiazolecarboxamide hydrochloride | 252003-71-7 | C20H24BrF2N5O3S*ClH |
| CEFTAROLINE中间体 | [4-(N-methylpyridinium-4-yl)-1,3-thiazol-2-yl]thiolate | 1427207-46-2 | C9H8N2S2 |
| CCT251545中间体C | 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole | 1607838-14-1 | C16H21BN2O2 |
| CBFβ抑制剂 | 5-Ethyl-4-(4-methoxy-phenyl)-thiazol-2-ylamine | 493028-20-9 | C12H14N2OS |
| C.I.酸性棕355 | Chromate(3-), (3-((4,5-dihydro-3-methyl-5-(oxo-kappaO)-1-phenyl-1H-pyrazol-4-yl)azo-kappaN1)-2-(hydroxy-kappaO)-5-nitrobenzenesulfonato(3-))(3-(hydroxy-kappaO)-4-((2-(hydroxy-kappaO)-1-naphthalenyl)azo-kappaN1)-7-nitro-1-naphthalenesulfonato(3-))-, triammonium | 73514-04-2 | C36H32CrN11O14S2 |
| C.I.酸性棕283 | Chromate(2-), (2,4-dihydro-4-((2-(hydroxy-kappaO)-5-nitrophenyl)azo-kappaN1)-5-methyl-2-phenyl-3H-pyrazol-3-onato(2-)-kappaO3)(2-(hydroxy-kappaO)-3-((2-(hydroxy-kappaO)-1-naphthalenyl)azo-kappaN1)-5-nitrobenzenesulfonato(3-))-, sodium hydrogen | 70815-17-7 | C32H20CrN8O11S- |
| C.I.分散蛋黄27 | Isoxazolo[5,4-d][1,3]thiazepine | 27629-49-8 | C6H4N2OS |
| C.I.分散蓝96 | 2,2'-[3-Methyl-4-(5-nitrothiazol-2-ylazo)phenylimino]bisethanol | 72987-42-9 | C14H17N5O4S |
| C-[3-(4-氯苯基)-1H-吡唑-4-基]-甲胺 | C-[3-(4-Chloro-phenyl)-1H-pyrazol-4-yl]-methylamine | 1020052-19-0 | C10H10ClN3 |
| C-[3-(3,4-二甲氧基-苯基)-[1,2,4]噁二唑-5-基]-甲胺 | 1-[3-(3,4-Dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]methanamine | 878977-92-5 | C11H13N3O3 |
| C-[3-(2-氯-苯基)-[1,2,4]噁二唑-5-基]-甲胺 | [3-(2-Chlorophenyl)-1,2,4-oxadiazol-5-yl]methanamine | 883548-05-8 | C9H8ClN3O |
| C-[2-(4-氯-苯基)-噻唑-4-基]-甲基胺 | (2-(4-chlorophenyl)thiazol-4-yl)methanamine hydrochloride | 690632-35-0 | C10H9ClN2S*ClH |
| C-(5-苯基-4H-[1,2,4]噻唑-3-基)-甲基胺 | 1-(5-phenyl-4H-1,2,4-triazol-3-yl)methanamine dihydrochloride | 1221726-04-0 | C9H10N4*2ClH |
| C-(2-甲基-4-三氟甲基-5-噻唑)-甲胺 | (2-Methyl-4-(trifluoromethyl)thiazol-5-yl)methanamine | 1283720-60-4 | C6H7F3N2S |
| C-(2-溴-噻唑-5-基)-甲胺 | (2-Bromothiazol-5-yl)methanamine hydrochloride | 1001413-46-2 | C4H5BrN2S*ClH |
| BMS-687453抑制剂 | BMS-687453 | 1000998-59-3 | C22H21ClN2O6 |
| B-[1-[2-(二甲基氨基)乙基]-1H-吡唑-4-基]硼酸 | (1-(2-(Dimethylamino)ethyl)-1H-pyrazol-4-yl)boronic acid | 1086063-73-1 | C7H14BN3O2 |
| B-2H-四唑-5-基-硼酸 | tetrazole-5-boronic acid | 851519-08-9 | CH3BN4O2 |
| B-(5-甲基-1H-吡唑-3-基)硼酸 | <sub>(5-methyl-1H-pyrazol-3-yl)boronic acid</sub> | 1163248-54-1 | C4H7BN2O2 |
| B-(4-咪唑并[1,2-a]吡啶-2-苯基)硼酸 | (4-(imidazo[1,2-a]pyridin-2-yl)phenyl)boronic acid | 607740-02-3 | C13H11BN2O2 |
| B-(2-甲基-4-噻唑)硼酸 | 2-Methylthiazole-4-boronic acid | 1246761-85-2 | C4H6BNO2S |
| B-(1-甲基-1H-咪唑-4-基)硼酸 | (1-methyl-1H-imidazol-4-yl)boronic acid | 957720-01-3 | C4H7BN2O2 |
| B-(1-甲基-1H-吡唑-3-基)-硼酸 | (1-methyl-1H-pyrazol-3-yl)boronic acid | 869973-96-6 | C4H7BN2O2 |
| Alpha-(氯甲基)-2-羟基甲基-5-硝基咪唑-1-乙醇 | alpha-(Chloromethyl)-2-hydroxymethyl-5-nitroimidazole-1-ethanol | 62580-79-4 | C7H10ClN3O4 |
| APD668抑制剂 | JNJ-28630368 | 832714-46-2 | C21H24FN5O5S |
| AKT1/AKT2变构抑制剂(BAY1125976) | BAY-1125976 | 1402608-02-9 | C23H21N5O |
| 9H-嘌呤,6-氯-9-(4-氯苯基)- | 6-chloro-9-(4-chlorophenyl)-9H-purine | 103566-04-7 | C11H6Cl2N4 |
| 9H-嘌呤,2-甲氧基-9-苯基- | 2-methoxy-9-phenyl-9H-purine | 118807-49-1 | C12H10N4O |
| 9-苯基胍 | 9-phenylguanine | 14443-33-5 | C11H9N5O |
| 9-苯基-3H-嘌呤-6-酮 | 9-phenylhypoxanthine | 6334-42-5 | C11H8N4O |
| 9-苯基-1,7-二氮杂双环[4.3.0]壬-2,4,6,8-四烯 | 3-phenylimidazo[1,2-a]pyridine | 92961-15-4 | C13H10N2 |
| 9-甲基-8-苯基嘌呤-6-胺 | 6-amino-9-methyl-8-phenyl-9H-purine | 30720-73-1 | C12H11N5 |
| 9-甲基-6,12-二苯基-9H-二[1,2,4]三唑并[4,3-a:3',4'-d][1,5]苯并二氮卓 | 9-methyl-6,12-diphenyl-9H-bis<1,2,4>triazolo<4,3-a:3',4'-d><1,5>benzodiazepine | 133118-27-1 | C24H18N6 |
| 9-甲基-3-(4-硝基苯基)-6-丙基-6,9-二氢-5H-[1,2,4]三唑并[3,4-i]嘌呤-5-酮 | 5H-1,2,4-Triazolo(3,4-i)purin-5-one, 6,9-dihydro-9-methyl-3-(4-nitrophenyl)-6-propyl- | 135445-87-3 | C16H15N7O3 |
| 9-氯-5,6-二氢-4-甲基-1-苯基-4H-[1,2,4]三唑并[4,3-a][1,5]苯并二氮杂卓 | 9-chloro-4-methyl-1-phenyl-5,6-dihydro-4<i>H</i>-benzo[<i>b</i>][1,2,4]triazolo[4,3-<i>d</i>][1,4]diazepine | 54028-81-8 | C17H15ClN4 |
| 9-[4,5-二(苯基)-1,3-恶唑-2-基]壬酸 | 4,5-diphenyl-2-oxazolenonanoic acid | 136451-54-2 | C24H27NO3 |
| 9-[3,4,5-三(苯基)吡唑-1-基]壬酸 | 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid | 134701-70-5 | C30H32N2O2 |
| 9-(对-硝基苯基)腺嘌呤 | 9-(4-nitrophenyl)adenine | 21314-05-6 | C11H8N6O2 |
| 9-(4-甲氧基苯基)嘌呤-2,6-二胺 | 2,6-Diamino-..p..-methoxyphenylpurin | 49753-42-6 | C12H12N6O |